. 2023 May 3;34(8):1305–1314. doi: 10.1681/ASN.0000000000000152
Copyright © 2023 The Author. Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 3.
Merits and caveats of the target trial emulation framework.